Breast Cancer Clinical Trial
ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Summary
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in the advanced setting).
Full Description
This is a first in human, Phase 1/2, open label, dose escalation and dose expansion study that consists of two stages:
Phase 1: A dose escalation stage to determine the MTD/RP2D of ORIN1001 when given as a single agent in up to 30 subjects with advanced solid tumors. In addition, a dose escalation stage to determine the MTD/RP2D of daily ORIN1001 in combination with Abraxane given intravenously in up to 18 subjects with relapsed refractory metastatic breast cancer (TNBC or ER+ HER2-).
Phase 2: An expansion stage of ORIN1001 alone (Cohort A: TNBC) and in combination with Abraxane (Cohort B: Myc+; Cohort C: ER+ HER2-, and Cohort D: TNBC) to estimate efficacy in up to 120 subjects with relapsed refractory metastatic breast cancer.
Eligibility Criteria
Inclusion Criteria:
For dose escalation with ORIN1001 alone:
-Male or female with advanced solid tumors for which no effective standard of care treatments are available
For dose escalation with ORIN1001 in combination with Abraxane:
-Males or females with relapsed refractory metastatic breast cancer (TNBC or ER+, HER2-) must have progressed through at least 2 lines of therapy and for whom there are no available therapies that confer a clinical benefit
For dose expansion:
a. Males or females with relapsed refractory metastatic breast cancer including:
TNBC (i.e. estrogen receptor (ER)-, progesterone receptor-, and human epidermal growth factor receptor 2 [HER2]-)
ER+ HER2- breast cancer
Inclusion Criteria for Dose Escalation and Dose Expansion
Adults aged ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Life expectancy of 3-4 months
Have at least one measurable lesion per RECIST 1.1
Have adequate organ function, including all of the following:
Adequate bone marrow reserve as defined by: ANC≥1.0 x 10 9/L; platelet count ≥75 x 10 9/L; hemoglobin ≥9 g/dL
Hepatic: total bilirubin ≤2 x ULN, transaminases (AST/SGOT and/or ALT/SGPT) ≤ 3X ULN;alkaline phosphatase ≤ 5 x ULN
Renal: 24-hour creatinine clearance ≥ 30 mL/min calculated
Adequate tissue sample from either archival tumor tissue or fresh biopsy of tumor at the screening for tumor genotyping.
Male subjects must be surgically sterile or must agree to use physician approved contraception for 7 days prior to the first study drug administration to 30 days after the last dose of study treatment.
Women of childbearing potential must have negative serum pregnancy test within 14 days prior the first administration of study drug and agree to use physician-approved contraception from 30 days prior to the first study drug administration to 30 days following the last study drug administration.
Ability to understand and willingness to sign an informed consent prior to any study specific procedures.
Resolution of all toxicities (except alopecia) from prior therapy to ≤ Grade 1 (CTCAE v5)
Exclusion Criteria:
Does not meet inclusion criteria
Received any of the following within the specified time frame prior to the first administration of study drug:
i. Excluding those with a history of coagulopathy ii. Excluding those who require concurrent use of anti-coagulants or anti-platelet medication, with exception of aspirin doses ≤ 81 mg/day, prophylaxis subcutaneous (SC) heparin or SC low-molecular weight heparin for deep vein thrombosis (DVT) prophylaxis or heparin flushes to maintain IV catherer patency iii. Excluding subjects that have Prothrombin time (PT)/international normalized ratio (INR) or activated partial thromboplastin time (aPTT) >1.5 x ULN b.Prior chemotherapy or other systemic anticancer therapy within 3 weeks or 5 times the plasma half-life of the drug, whichever is shorter; c.Prior radiotherapy within 2 weeks; d.Major surgery within 2 weeks; e.Prior treatment with investigational drugs within 4 weeks; f. Myocardial infarction, uncontrolled angina,severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the fist dose of study drug
Greater than Class II heart failure using New York Heart Association (NYHA) criteria
The subject has uncontrolled human immunodeficiency virus (HIV) infection or active hepatitis B or C infection or other known active and/or uncontrolled infection
Active autoimmune disease that is not appropriately controlled with treatment
Active malignancy with the exception of:
adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
adequately treated stage I cancer from which the subject is currently in remission, or
any other cancer from which the subject has been disease-free for ≥3 years;
Any serious uncontrolled medical or psychological disorder that would impair the ability to receive protocol therapy
Any condition which places the subject at unacceptable risk or confounds the ability of the investigator to interpret study data
The subject is pregnant or lactating woman. Any woman who becomes pregnant during the study will be withdrawn from the study.
Known active uncontrolled or symptomatic brain metastases. Patients with a history of such metastases that have been treated and are stable ≥28 days may be enrolled. Patients with no steroid use for at least 2 weeks prior to the time of enrollment are permitted.
Failed to respond to the most recent dose of Abraxane and must have been received at least 12 months prior to starting treatment.(combination arm only)
Greater than Grade 1 neuropathy (combination arm only)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
Gilbert Arizona, 85234, United States
Tucson Arizona, 85719, United States
Burbank California, 91505, United States
Laguna Hills California, 92653, United States
Orange California, 92868, United States
Westwood California, 90024, United States
Denver Colorado, 80045, United States
Highlands Ranch Colorado, 80129, United States
Lone Tree Colorado, 80124, United States
Miami Florida, 33136, United States
Wichita Kansas, 67214, United States
Kansas City Missouri, 64111, United States
Buffalo New York, 14203, United States
New Hyde Park New York, 11042, United States
New Hyde Park New York, 11042, United States
New York New York, 10016, United States
Canton Ohio, 44718, United States
Philadelphia Pennsylvania, 19107, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?